Non-small cell lung cancer

News

ASCO: AstraZeneca’s triple whammy in lung and breast cancer

Two impressive studies in lung cancer and another in breast cancer made Sunday a stellar day for AstraZeneca at the ASCO congress.

News

ASCO: Gilead sifts lung cancer data for efficacy crumbs

Gilead Sciences’ bid to extend the uses of TROP2-directed Trodelvy into lung cancer currently rests on the results of its EVOKE-01 study, revealed for the first time at th

News

Susan Galbraith, executive vice-president, Oncology R&D, AstraZeneca

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

The overall survival (OS) data has come in from the TROPION-Lung01 study of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in lung cancer – and the res

News

Jacobio plans bid for China’s KRAS market with safety edge

Jacobio Pharma has reported the results of its pivotal Chinese study of KRAS G12C inhibitor glecirasib, with a safety profile that could differentiate it from other drugs

News

J&J gets CHMP nod for Rybrevant in first-line lung cancer

Johnson & Johnson’s Rybrevant is on the brink of EU approval as a treatment for a subset of patients with newly diagnosed EGFR-positive lung cancer, after a recommenda

News

EU OK sets up first ex-China launches for BeiGene's Tevimbra

BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside

ASCO: AstraZeneca’s triple whammy in lung and breast cancer

ASCO: Gilead sifts lung cancer data for efficacy crumbs

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

Jacobio plans bid for China’s KRAS market with safety edge

J&J gets CHMP nod for Rybrevant in first-line lung cancer

EU OK sets up first ex-China launches for BeiGene's Tevimbra

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Non-small cell lung cancer

Editor's Picks